2-bromo-2-methyl-propionyl isocyanate | 50827-94-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-bromo-2-methyl-propionyl isocyanate
• 英文别名: 2-bromo-2-methylpropanoyl isocyanate；2-Bromo-2-methylpropanoyl isocyanate
• CAS: 50827-94-6
• 化学式: C₅H₆BrNO₂
• 分子量: 192.012
• InChiKey: GQHJANQBJJKHAO-UHFFFAOYSA-N

物化性质

• 沸点：
  174.6±23.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  46.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-2-methyl-propionyl isocyanate 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 5,5-dimethyl-1-[5-(5-nitro-furan-2-yl)-[1,3,4]thiadiazol-2-yl]-imidazolidine-2,4-dione
  参考文献：
  名称：

  硝基呋喃基杂环。3。

  摘要：

  DOI：

  10.1021/jm00269a023
• 作为产物：
  描述：

  草酰氯 、 2-溴异丁酰胺 以 1,2-二氯乙烷 为溶剂， 反应 1.0h， 生成 2-bromo-2-methyl-propionyl isocyanate
  参考文献：
  名称：

  平面手性钌配合物的不对称自动串联催化：顺序烯丙基酰胺化和原子转移自由基环化

  摘要：

  Ru完成了所有工作：描述了一个由平面手性环戊二烯基-钌络合物催化的不对称自串联反应的新例子。烯丙基氯与α-卤代酰胺的反应通过一锅顺序的烯丙基酰胺化/原子转移自由基环化反应提供了合成有用的，非对映异构和对映异构体富集的具有多个立体异构中心的γ-内酰胺。PG ＝保护基。

  DOI：

  10.1002/anie.201300485

文献信息

• Benzoxepin PI3K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08263633B2

  公开（公告）日：2012-09-11

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C（R7）2，（x）X1为C（R7）2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，对于抑制脂质激酶包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病是有用的。公式I化合物的使用方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病，或相关的病理条件。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噻吩化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；当(i) X1为N且X2为S，(ii) X1为S且X2为N，(iii) X1为CR7且X2为S，(iv) X1为S且X2为CR7，(v) X1为NR8且X2为N，(vi) X1为N且X2为NR8，(vii) X1为CR7且X2为O，(viii) X1为O且X2为CR7，(ix) X1为CR7且X2为C(R7)2，(x) X1为C(R7)2且X2为CR7，(xi) X1为N且X2为O，或(xii) X1为O且X2为N，对于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病有用。本文还公开了使用公式I化合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Nitrofuryl heterocyclics. 1
  作者：M. D. Closier、Peter J. Islip

  DOI：10.1021/jm00298a013

  日期：1970.7.1
• Asymmetric Auto-Tandem Catalysis with a Planar-Chiral Ruthenium Complex: Sequential Allylic Amidation and Atom-Transfer Radical Cyclization
  作者：Naoya Kanbayashi、Kazuhiro Takenaka、Taka-aki Okamura、Kiyotaka Onitsuka

  DOI：10.1002/anie.201300485

  日期：2013.4.26

  asymmetric auto‐tandem reaction catalyzed by a planar‐chiral cyclopentadienyl–ruthenium complex is described. The reaction of allylic chloride with α‐haloamides provides synthetically useful, diastereomerically and enantiomerically enriched γ‐lactams with multiple stereogenic centers through one‐pot sequential allylic amidation/atom‐transfer radical cyclization. PG=protecting group.

  Ru完成了所有工作：描述了一个由平面手性环戊二烯基-钌络合物催化的不对称自串联反应的新例子。烯丙基氯与α-卤代酰胺的反应通过一锅顺序的烯丙基酰胺化/原子转移自由基环化反应提供了合成有用的，非对映异构和对映异构体富集的具有多个立体异构中心的γ-内酰胺。PG ＝保护基。
• Nitrofuryl heterocyclics. 3
  作者：Peter J. Islip、Madelaine R. Johnson

  DOI：10.1021/jm00269a023

  日期：1973.11